Search and analyze individual stocks with comprehensive metrics
Emcure Pharmaceuticals Limited
Fundamental Score
Emcure Pharmaceuticals Limited Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of EMCURE across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (18.51%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.72%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (20.45%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Robust Profit Growth (45.28%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (15.72%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Excellent EPS Growth (34.81% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (36.07% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.23)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (8.43x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹2541.67 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Risk Factors
2 factors identified
Limited Institutional Interest (FII+DII: 5.70%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Emcure Pharmaceuticals Limited
About EMCURE
Company Details
Market Information
Performance
EMCURE Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of EMCURE?
EMCURE is currently trading at ₹1370.60 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of EMCURE shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of EMCURE and what does it mean?
EMCURE has a P/E ratio of 33.46x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹33 for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.
How is EMCURE performing according to Bull Run's analysis?
EMCURE has a Bull Run fundamental score of 70.4/100, which indicates strong fundamentals and excellent investment quality. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 18.51%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does EMCURE belong to?
EMCURE operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Emcure Pharmaceuticals Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for EMCURE?
EMCURE has an ROE of 18.51%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Emcure Pharmaceuticals Limited generates profits from shareholders' equity. An ROE of 19% means the company generates ₹19 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is EMCURE's debt-to-equity ratio and what does it indicate?
EMCURE has a debt-to-equity ratio of 0.23, which indicates conservative financing with low financial risk. This means the company has ₹23 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is EMCURE's dividend yield and is it a good dividend stock?
EMCURE offers a dividend yield of 0.23%, which means you receive ₹0.23 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has EMCURE grown over the past 5 years?
EMCURE has achieved 5-year growth rates of: Sales Growth 9.36%, Profit Growth 36.07%, and EPS Growth 34.81%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in EMCURE and why does it matter?
Promoters hold 77.91% of EMCURE shares, with 0.04% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: -0.01%.
How does EMCURE compare with its industry peers?
EMCURE trades at P/E 33.46x vs industry average 33.97x, with ROE of 18.51% and ROCE of 20.72%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether EMCURE is outperforming its competitive set in profitability, growth, and valuation metrics.
What is EMCURE's market capitalization and what category does it fall into?
EMCURE has a market capitalization of ₹25194 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for EMCURE?
Key ratios for EMCURE: ROE 18.51% (Excellent), ROCE 20.72%, P/E 33.46x, Debt-to-Equity 0.23, Interest Coverage 8.43x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is EMCURE stock and what is its beta?
EMCURE has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for EMCURE?
EMCURE has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹1370.60, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in EMCURE?
Key risks for EMCURE include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.23), and operational challenges. The stock has a Fundamental Score of 70.4/100, indicating strong fundamentals with lower risk profile. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is EMCURE's operating profit margin and how has it trended?
EMCURE has a 5-year average Operating Profit Margin (OPM) of 20.45%, which is excellent and indicates strong pricing power and cost control. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. This strong margin indicates competitive advantages and operational leverage. Compare with industry peers to understand relative performance.
How is EMCURE's quarterly performance in terms of sales and profit growth?
EMCURE's recent quarterly performance shows YoY Sales Growth of 15.72% and YoY Profit Growth of 45.28%. This strong double-digit growth indicates excellent business momentum and management execution. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in EMCURE?
EMCURE has FII holding of 2.86% and DII holding of 2.84%, totaling 5.70% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.